ERBB2 and triple-negative breast carcinoma: The majority of cohorts included mixed breast cancer histology (39.8%), while 36.4% included only ER positive patients, 13.6% only HER2 positive patients, 5.7% HER2 negative histology and 4.6% only triple negative breast cancer patients (Supplementary Table 2).